Britain's National Institute for Health and Clinical Excellence has to decide whether the NHS will pay for Revlimid, a cancer drug that can extend life but costs the health service dearly for every patient treated. Director Adam Wishart gets inside the room where that decision gets made, filming NICE's own committee members as they weigh cost against benefit, alongside interviews with patients waiting to hear if the drug will be approved for them and executives from the pharmaceutical company that developed it and stands to profit from the ruling. The film lays out the arithmetic NICE actually uses, the cost-per-quality-adjusted-life-year threshold that decides which treatments the NHS can afford, and shows what that number means to someone whose survival depends on the outcome. Pharmaceutical pricing gets scrutiny too, since the same drug that NICE calls too expensive was priced that way by the company sitting across the table from it. No side gets to be simply right; the film just shows the meeting where the tradeoff becomes unavoidable.